NVCR – NovoCure Limited
Float Short %
8.3
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
-0.07
EPS Last/This Y
0.18
EPS This/Next Y
-0.11
Price
13.45
Target Price
24.07
Analyst Recom
1.57
Performance Q
-2.96
Relative Volume
0.58
Beta
0.72
Ticker: NVCR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | NVCR | 13.47 | 0.20 | 0.11 | 28808 |
| 2025-12-29 | NVCR | 13.31 | 0.20 | 0.06 | 28920 |
| 2025-12-30 | NVCR | 13.23 | 0.20 | 0.16 | 29077 |
| 2025-12-31 | NVCR | 12.92 | 0.20 | 0.11 | 29391 |
| 2026-01-02 | NVCR | 13.11 | 0.20 | 0.26 | 29759 |
| 2026-01-05 | NVCR | 13.78 | 0.20 | 1.82 | 29818 |
| 2026-01-06 | NVCR | 14.31 | 0.20 | 0.06 | 30081 |
| 2026-01-07 | NVCR | 14.4 | 0.20 | 2.98 | 31117 |
| 2026-01-08 | NVCR | 14.88 | 0.22 | 0.68 | 31705 |
| 2026-01-09 | NVCR | 14.35 | 0.22 | 1.21 | 31882 |
| 2026-01-12 | NVCR | 14.19 | 0.23 | 1.98 | 32079 |
| 2026-01-13 | NVCR | 13.66 | 0.24 | 2.14 | 32618 |
| 2026-01-14 | NVCR | 13.78 | 0.25 | 1.37 | 32978 |
| 2026-01-15 | NVCR | 13.78 | 0.25 | 0.10 | 33289 |
| 2026-01-16 | NVCR | 13.64 | 0.25 | 2.26 | 33385 |
| 2026-01-20 | NVCR | 13.02 | 0.15 | 0.36 | 18061 |
| 2026-01-21 | NVCR | 13.52 | 0.15 | 0.58 | 18237 |
| 2026-01-22 | NVCR | 14.19 | 0.16 | 1.11 | 18830 |
| 2026-01-23 | NVCR | 13.45 | 0.18 | 0.66 | 19772 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | NVCR | 13.47 | 35.6 | -40.3 | -1.38 |
| 2025-12-29 | NVCR | 13.27 | 35.6 | -36.7 | -1.38 |
| 2025-12-30 | NVCR | 13.23 | 35.6 | -39.2 | -1.38 |
| 2025-12-31 | NVCR | 12.92 | 35.6 | -35.3 | -1.38 |
| 2026-01-02 | NVCR | 13.11 | 35.6 | -42.5 | -1.38 |
| 2026-01-05 | NVCR | 13.77 | 35.6 | -49.7 | -1.38 |
| 2026-01-06 | NVCR | 14.29 | 35.6 | -47.1 | -1.38 |
| 2026-01-07 | NVCR | 14.40 | 35.6 | -41.2 | -1.38 |
| 2026-01-08 | NVCR | 14.87 | 35.6 | -46.0 | -1.38 |
| 2026-01-09 | NVCR | 14.34 | 35.6 | -32.8 | -1.38 |
| 2026-01-12 | NVCR | 14.20 | 35.6 | -37.7 | -1.38 |
| 2026-01-13 | NVCR | 13.67 | 35.6 | -32.7 | -1.38 |
| 2026-01-14 | NVCR | 13.79 | 34.4 | -41.8 | -1.38 |
| 2026-01-15 | NVCR | 13.80 | 34.4 | -52.0 | -1.38 |
| 2026-01-16 | NVCR | 13.64 | 34.4 | -49.3 | -1.38 |
| 2026-01-20 | NVCR | 13.00 | 33.5 | -41.8 | -1.38 |
| 2026-01-21 | NVCR | 13.57 | 33.5 | -60.8 | -1.38 |
| 2026-01-22 | NVCR | 14.20 | 33.5 | -61.3 | -1.38 |
| 2026-01-23 | NVCR | 13.45 | 33.5 | -40.6 | -1.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | NVCR | 0.89 | -5.30 | 6.91 |
| 2025-12-29 | NVCR | 0.89 | -5.29 | 6.91 |
| 2025-12-30 | NVCR | 0.89 | -5.29 | 6.91 |
| 2025-12-31 | NVCR | 0.89 | -5.29 | 6.91 |
| 2026-01-02 | NVCR | 0.89 | -5.29 | 6.91 |
| 2026-01-05 | NVCR | 0.89 | -5.30 | 6.91 |
| 2026-01-06 | NVCR | 0.89 | -5.30 | 6.91 |
| 2026-01-07 | NVCR | 0.89 | -5.30 | 6.91 |
| 2026-01-08 | NVCR | 0.89 | -5.30 | 6.91 |
| 2026-01-09 | NVCR | 0.89 | -5.30 | 6.91 |
| 2026-01-12 | NVCR | 0.85 | -5.30 | 6.91 |
| 2026-01-13 | NVCR | 0.89 | -5.30 | 8.30 |
| 2026-01-14 | NVCR | 0.85 | -5.30 | 8.30 |
| 2026-01-15 | NVCR | 0.89 | -5.30 | 8.30 |
| 2026-01-16 | NVCR | 0.89 | -5.30 | 8.30 |
| 2026-01-20 | NVCR | 0.89 | -5.25 | 8.30 |
| 2026-01-21 | NVCR | 0.89 | -5.25 | 8.30 |
| 2026-01-22 | NVCR | 0.89 | -5.25 | 8.30 |
| 2026-01-23 | NVCR | 0.89 | -5.25 | 8.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.33
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-0.4
Insider Transactions
0.89
Institutional Transactions
-5.25
Beta
0.72
Average Sales Estimate Current Quarter
168
Average Sales Estimate Next Quarter
168
Fair Value
Quality Score
28
Growth Score
37
Sentiment Score
39
Actual DrawDown %
94.2
Max Drawdown 5-Year %
-95.2
Target Price
24.07
P/E
Forward P/E
PEG
P/S
2.35
P/B
4.41
P/Free Cash Flow
EPS
-1.61
Average EPS Est. Cur. Y
-1.38
EPS Next Y. (Est.)
-1.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-27.66
Relative Volume
0.58
Return on Equity vs Sector %
-79.3
Return on Equity vs Industry %
-69.3
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-40.6
NovoCure LimitedSector: Healthcare
Industry: Medical Devices
Employees: 1488
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading